Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Allergic Rhinitis

In brief

We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Key facts

Study ID: NCT00584987
Run by: University of Chicago
People needed: 64
Starts: 2007-06-01
Expected to finish: 2009-07-01
Last updated by the study team: 2013-12-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Males and females between 18 and 55 years of age.
History of perennial allergic rhinitis.
Positive skin test to dust mite, dog, cat or indoor mold antigen.
And a combined nasal morning and evening score of ≥4 for nasal congestion in the day preceding entry

You may not qualify if…

Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
Pregnant or lactating women.
Subjects treated with systemic steroids during the previous 30 days.
Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
Subjects treated with oral antihistamine/decongestants during the previous seven days.
Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
Subjects treated with immunotherapy and are escalating their dose.
Subjects on chronic anti-asthma medications.
Subjects with polyps in the nose or a significantly displaced septum.
Upper respiratory infection within 14 days of study start.

Where it is running

University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.